Market research
BX2.F BioXcel Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- 0.0
- Analyst target
- 92.55
- Dividend yield
- Not available
- Beta
- 0.29
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US09075P1057
- Market cap
- 9M
- P/E ratio
- 0.0
- Analyst target
- 92.55
- Dividend yield
- Not available
- Beta
- 0.29
About
About BioXcel Therapeutics, Inc
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BX2.F discussion.
5 years, 5 months ago
BioXcel Therapeutics, Inc is currently in a long term downtrend where the price is trading 38.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
BioXcel Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 154.8% to $-21M since the same quarter in the previous year.
Finally, its free cash flow fell by 159.2% to $-21M since the same quarter in the previous year.
Based on the above factors, BioXcel Therapeutics, Inc gets an overall score of 1/5.